chiosis, and Ehrlichia ewingii, were identified as agents of newly recognized diseases in the United States, which were collectively termed the ehrlichioses [1] [2] [3] . Concurrent infection with E. chaffeensis in an HIV-infected patient was first described in 1993, and subsequent reports have been sporadic [4] [5] [6] [7] [8] [9] . Infections with the agent of human granulocytic ehrlichiosis or E. ewingii have not been described in this patient cohort.
In persons infected with HIV, ehrlichiosis caused by E. chaffeensis is often life threatening [4, 6, 7, 9]; however, the disease responds well to specific therapy with tetracyclines, particularly when these antibiotics are given early in the course of the infection. In this report, we review and summarize the clinical courses and laboratory evaluations of 6 previously described patients and 15 newly reported patients who were coinfected with HIV and either E. chaffeensis or E. ewingii. [4] [5] [6] [7] [8] [9] . When available, supplementary clinical data were collected from the authors of these reports. Additional cases were identified passively in the course of routine patient care by infectious disease physicians practicing in clinics, hospitals, or medical centers in Arkansas, Florida, Georgia, Missouri, Oklahoma, and Tennessee from May 1997 through July 2000. Confirmed and suspected cases were reported to Centers for Disease Control and Prevention (CDC; Atlanta) during consultations or requests for confirmatory laboratory testing. Epidemiological and clinical data for each patient were abstracted from clinic and hospital records.
METHODS

Identification of patients. Published cases of ehrlichiosis in persons infected with HIV were reviewed and summarized
Laboratory confirmation. Clinical samples were obtained from patients during or shortly after their illnesses and tested using confirmatory assay(s). Peripheral blood, buffy coat, or bone marrow aspirate smears were stained with eosin-azure (Romanovsky)-type stains and examined for the presence of characteristic intracellular bacterial aggregates (morulae) in patient leukocytes. Patient serum or plasma samples were evaluated for antibodies reactive with E. chaffeensis by using indirect immunofluorescence assays (IFAs), as described elsewhere [10] .
Nucleic acid amplification was done with DNA extracted from samples of whole blood, peripheral blood leukocyte preparations, serum, plasma, or bronchoalveolar lavage fluid, as described elsewhere [3, 11] . One or more genomic regions were amplified from extracted DNA using PCR assays. Regions of the 16S rRNA gene of E. chaffeensis were amplified with primer pairs HE1 and HE3 [12] or EhrlU (5'-AGAACGAACGCTGGCGGCAAG) and EhrlL (5'-TAGGTACCGTCATTATCTTCCCTA) in a direct assay, or by a nested assay with primers 8F and 1448R in the primary reaction and primers HEl and GAIUR in the nested reaction [13] . Primers FB3 and FB5 were used to amplify the VLPT gene [11] , and primers F1 and R2 were used to amplify the 120-kDa protein gene [14] of E. chaffeensis. Regions of the 16S rRNA gene of E. ewingii were amplified directly by using primers EWF1 (5'-TCGAACGAACAATTCCTAAA) and HE3 or EWI and HE3 [3] . A region of the groESL heat-shock operon of E. ewingii was amplified in a nested PCR with primers HS1 and HS6 in the primary reaction and primers EWNFI and EWNR2 in the nested reaction [15] . PCR products were evaluated by complete or by partial sequencing to verify identity, as described elsewhere [3, 11, 13, 15] .
Formalin-fixed, paraffin-embedded bone marrow biopsy samples or autopsy tissues were stained with immunohistochemical stains, as described elsewhere [4, 16, 17] . For isolation of E. chaffeensis, peripheral blood leukocytes were separated from 3-5 mL of acute-phase whole blood and inoculated into DH82 cell cultures, as described elsewhere [7, 13] . The identity of each isolate was confirmed by means of PCR and sequencing. Statistical analyses. Significance tests were done with Fisher's exact test, for dichotomous variables, and the MannWhitney U test, for continuous variables; a P value of <.05 was considered significant. Analyses were done using SPSS software for Windows (SPSS) [18] . Twenty patients (95%) were male, and the median age was 43 years (range, 31-56 years). Absolute CD4+ T lymphocyte counts were available for 20 patients; 14 patients (70%) had counts of <200 ceils/4L at or near the time that they presented for care. All patients but 1 had HIV infection diagnosed before they presented with ehrlichiosis. In general, patients infected with E. chaffeensis had lower CD4+ T lymphocyte counts and had been aware of their HIV-seropositive status for fewer years than had patients infected with E. ewingii at the time they presented for care (table 1) . Eleven patients (52%) had no prior opportunistic infection. For 5 patients (24%), oropharyngeal candidiasis had been the only prior infection associated with their immunodeficiency. Severe or life-threatening opportunistic infections (e.g., Pneumocystis carinii pneumonia, Candida esophagitis, tuberculosis, or disseminated infection with Mycobacterium avium) had occurred in 5 patients (24%) before the onset of their infection with an Ehrlichia species. According to the CDC surveillance classification for HIV infection, 14 patients presented with AIDS. Clinical categories were available for 20 patients in this series and included A2 (4 patients), A3 (7 patients), B2 (2 patients), B3 (3 patients), and C3 (4 patients) [19] .
RESULTS
Fourteen patients (67%) were receiving antibiotics that contained sulfa as chemoprophylaxis for P carinii. Approximately half of the patients were receiving combination antiretroviral regimens that included either a viral protease inhibitor or a nonnucleoside reverse transcriptase inhibitor (i.e., highly active antiretroviral therapy [HAART] (table 2) . Rash patterns were described as diffusely erythematous or morbilliform, or scattered petechiae or macules. Rashes showed varied distributions, from focal involvement of extremities to extensive involvement of chest and abdomen. All patients in this series presented with : 1 cytopenia, and thrombocytopenia was observed in all but 1 patient. Patients infected with E. chaffeensis were more likely to present with pancytopenia than were those infected with E. ewingii. Elevated hepatic aminotransferase levels were observed at presentation in all patients infected with E. chaffeensis but in only 2 (50%) of 4 patients infected with E. ewingii. Approximately 80% of all patients presented with mild to moderate hyponatremia (table 2). Less frequently noted electrolyte abnormalities included hypocalcemia, hypomagnesemia, and hypophosphatemia.
Eighteen patients (86%) were hospitalized for their illnesses (table 3) hemorrhage (in 1), and sepsis (in 1). For 8 patients (38%), ehrlichiosis was not considered until -4 days after initial evaluation. All persons for whom a diagnosis of ehrlichiosis was considered received doxycycline within the first 24 h after presenting for care, and those who survived their illnesses generally became afebrile within 2-3 days after receiving this antibiotic. Moderate to severe disease manifestations were reported for 15 patients (71%), predominantly among those infected with E. chaffeensis (table 3). Three (23%) of 13 patients infected with E. chaffeensis had acute respiratory distress syndrome diagnosed, and 2 others developed pulmonary failure that required mechanical ventilatory support. Pulmonary, intracranial, or gastrointestinal hemorrhage occurred in 3 patients (23%) who were infected with E. chaffeensis. Secondary fungal infections, including pulmonary and tracheobronchial aspergillosis and tracheobronchial candidiasis, occurred in 3 E. chaffeensisinfected patients (23%) during the course of hospital stays that lasted 10 days. Hematologic and biochemical abnormalities were significantly more pronounced in persons infected with E. chaffeensis than they were in E. ewingii-infected patients (table 3) . Platelet count nadirs of <50 X 109 cells/L were observed in 17 patients (8 1%) in this series; however, all 8 patients who had counts of <20 x 109 cells/L were infected with E. chaffeensis. Similarly, all 7 patients who had serum sodium levels of <130 mmol/L and all 8 patients who had serum creatinine levels of >1.5 mg/dL were infected with this agent.
Lumbar punctures were performed for 6 patients (29%). Three patients (50%) had mildly elevated WBC counts (range, 6-8 X 106 cells/L), with 85%-100% lymphocytes. Protein concentration was elevated in 4 patients (67%; range, 0.48-0.96 gIL). Cerebrospinal glucose levels were abnormally low (2.4 mmol/L) in 1 patient (17%) and elevated (4.5 mmolIL) in 1 patient.
Six patients died either directly of infection with E. chaffeensis or of complications associated with the illness. All patients with fatal disease for whom CD4+ T lymphocyte counts were available (5 patients) had counts of <200 cells/,uL; 4 patients (80%) had counts of <100 cells/,uL, and 2 patients (40%) had counts of <50 cellsl4AL. Case-fatality ratios for patients infected with E. chaffeensis at each of these CD4+ cell count break points were 62%, 67%, and 50%, respectively. Morulae were visualized in peripheral blood or bone marrow leukocytes of '60% of patients in this series for whom whole blood, buffy coat, or bone marrow aspirate smears were evaluated. When quantified, morulae of E. chaffeensis were identified in -1%-25% of leukocytes, predominantly monocytes, and occasionally in metamyelocytes and band neutrophils. Morulae of E. ewingii were seen in -5% of mature and immature neutrophils and in rare eosinophils of 1 patient.
Ehrlichial DNA was amplified from all but 2 patients tested; both negative specimens were acute-phase serum samples ob- In the United States, ehrlichiae were first identified as human pathogens in 1986. Expanding public and physician awareness of and improved epidemiological surveillance for infections caused by Ehrlichia species have contributed to increasing recognition of ehrlichioses in the general population. This is exemplified by recent increases in reported cases: -1200 cases of ehrlichioses were reported to state health departments from 1986 through 1997 [20] , but nearly 1300 cases were reported in 1998 and 1999 alone (CDC, unpublished data). Similarly, 81% of the patients described in this series of HIV-infected patients were identified during the period of 1997-2000. However, enhanced surveillance and awareness are perhaps only 2 of several elements involved in the emergence of E. chaffeensisand E. ewingii-associated illnesses in patients coinfected with HIV. Recent changes in the geographic distribution of persons with HIV disease and progress in the medical management of HIV-infected patients may also be contributing to the emergence of ehrlichioses in this patient population.
Most patients in this series resided or worked in nonmetropolitan areas, which is true of the majority of persons who have ehrlichioses diagnosed [20, 21] . Although the absolute preva-lence of HIV among persons in nonmetropolitan areas remains significantly lower than it is in urban centers, the number of HIV-infected persons residing in nonmetropolitan areas has increased steadily [22, 23] . From 1992 through 1995, the average annual increase in AIDS cases in nonmetropolitan areas was 30.0%, which exceeded the 25.8% increase observed in the largest metropolitan areas [24] . The increase in HIV infection in rural populations has been attributed to increased transmission in these areas and to migration of persons to their native communities for treatment and supportive care after acquiring HIV infection in urban centers [25] [26] [27] . The diffusion of HIV into rural populations is particularly evident in the southeastern United States [25] [26] [27] [28] [29] , which was the region with the greatest number of HIV infections during the mid-1990s [30] . This region also represents the origin of the majority of ehrlichiosis cases caused by E. chaffeensis [20] .
Approximately half of the patients in this series were receiving HAART, and most were in otherwise good health before the onset of their infection with an Ehrlichia species. Combination antiretroviral regimens have significantly slowed the progression of HIV disease in many persons, with concomitant decreases in the rates of hospitalization, morbidity, and mortality in patients for whom these drugs are available [30] [31] [32] [33] . In this context, new therapies for HIV offer a level of health that facilitates occupational and recreational pursuits that perhaps were not previously possible. Some of these activities (e.g., hunting, hiking, camping, or working outdoors) involve incursions into tick-infested habitats and are associated with risks of acquiring tickborne diseases. Severe disease caused by Rickettsia rickettsii, the agent of Rocky Mountain spotted fever, and Babesia microti, an agent of human babesiosis, have been reported recently for persons with advanced HIV disease [34, 35] . In this context, the emergence of a healthier HIV-infected patient population exposed to increasingly diverse environments may paradoxically accentuate increases in the incidence of some infectious diseases, such as ehrlichioses.
The full clinical spectrum of illnesses that result from infections with E. chaffeensis or E. ewingii in HIV-infected patients may eventually reveal milder forms of disease; however, it is apparent that ehrlichioses, and illness caused by E. chaffeensis in particular, can be severe or life threatening in this patient cohort. All but 3 patients in this series were eventually hospitalized, creating a possible selection bias for those patients with more-severe disease; however, comparisons with other series that include data for hospitalized patients suggest that ehrlichiosis caused by E. chaffeensis is more severe in HIV-infected persons than it is in the general population. In a series of 237 patients from the general population that included 146 hospitalized persons (62%), renal failure, disseminated intravascular coagulopathy, spontaneous hemorrhages, or cardiac manifestations attributable to ehrlichiosis were identified in only 3%-11% of persons infected with E. chaffeensis [21] . These same manifestations occurred in -15%-30% of the HIV-infected persons in this series. Contrasting mortality as a measure of disease severity, no deaths were reported among 41 patients hospitalized with E. chaffeensis infection described in separate prospective studies in Georgia, Missouri, North Carolina, and Tennessee from 1987 through 1998 [13, [36] [37] [38] ; however, onethird of the hospitalized HIV-infected patients in this series died of infection with this agent.
Severe disease attributable to E. chaffeensis has been described in patients with compromised immunity from other causes, including immunosuppressive therapies [39] [40] [41] [42] , monoclonal gammopathy [17] , or asplenia [5, 43] . A resurgent T cell lymphocytosis is frequently described in persons recovering from infection with E. chaffeensis [37, 44] , suggesting that intact T cell host responses are important for clearance of ehrlichiae. In this series, all patients with fatal disease had CD4+ T lymphocyte counts of <200 cells/4L. Case-fatality ratios for persons with <100 cells/,L were ?50%, in contrast with a case-fatality ratio in the general population of -3% [20] . In this context, ehrlichiae may represent opportunistic pathogens in HIV-infected persons.
Only 4 patients infected with E. ewingii have been reported previously in the literature, and 3 of these had underlying immunodeficiencies [3] . It is unclear whether E. ewingii causes disease primarily in immunosuppressed persons or if this bacterium is responsible for illnesses in a broader patient population, in which only the most clinically advanced cases have been recognized in a sentinel cohort. Only 2 (50%) of 4 patients with confirmed E. ewingii infection in this series were hospitalized, and all patients recovered completely from infection with this pathogen. The E. ewingii-infected patients reported in this series developed fewer disease manifestations and complications than did patients infected with E. chaffeensis. Although these findings suggest that E. ewingii may be less pathogenic than E. chaffeensis, the small number of patients evaluated to date precludes broad comparisons of severity between these 2 forms of ehrlichiosis in this patient population.
Host factors responsible for disease severity remain relatively undefined in persons infected with E. chaffeensis [7, 13] . A wide range of clinical outcomes was recognized soon after the initial identification of human ehrlichiosis in the United States [45] ; a spectrum of disease severity continues to be observed among persons infected with ehrlichiae. Severe and sometimes fatal illnesses have occurred in otherwise healthy young adults and children [5, 9, 46] . In contrast, relatively moderate disease caused by E. chaffeensis or E. ewingii occurred in several HIVinfected patients in this series, including some patients with CD4+ T lymphocyte counts of <200 cells/,uL. Genetic heterogeneity exists among different isolates of F. chaffeensis [7, 11, 13, 14] , which suggests that different strains of this bacterium may vary in phenotypic or biological characteristics that influence pathogenicity [7, 13] . Other studies have demonstrated that factors extrinsic to the host or pathogen, particularly delay in treatment with an appropriate antibiotic (e.g., a tetracycline), can be associated with an increased risk for disease complications and death in persons infected with ehrlichiae [21] . A combination of factors, including the immune status of the patient, the interval from symptom onset to correct diagnosis and initiation of effective therapy, and, perhaps, the virulence of the bacterial isolate infecting the patient, may ultimately represent important and interacting determinants of the clinical outcome of ehrlichioses.
Most presenting signs and symptoms (e.g., fever, headache, malaise, myalgia, and nausea) were nonspecific and similar in frequency to those described in other case series of patients infected with E. chaffeensis or E. ewingii [ 3, 21, 37, 43, 47] . Diagnosis of ehrlichioses in persons coinfected with HIV may be confounded by clinical similarity with various communityacquired or conventionally recognized opportunistic infections in this patient population. As with many other systemic diseases in persons infected with HIV, ehrlichioses may present with multiple and varied signs and symptoms, including vomiting, diarrhea, rash, or cough. Leukopenia, thrombocytopenia, and anemia occurred with frequencies similar to those described in prospective series of E. chaffeensis-infected patients in the general population; however, median nadir values for each value were markedly lower in HIV-infected patients [13, 36, 37, 47]. Cytopenia, although a characteristic finding of ehrlichioses, is perhaps less indicative of these illnesses in HIV-infected patients than it is in the general population, and it can be caused by HIV disease, other opportunistic infections, or various antimicrobial therapies used by this patient cohort [48, 49] .
Several of the patients in this series initially had other conditions diagnosed, and one-third of the patients received empirical therapy with 1 antibiotic that was ineffective against ehrlichiae (e.g., cephalosporins, macrolides, and sulfa antimicrobials). Doxycycline, the drug of choice for ehrlichioses, is not routinely administered as empirical therapy for febrile patients infected with HIV. Two-thirds of the patients were receiving trimethoprim-sulfamethoxazole or dapsone as chemoprophylaxis for R carinii pneumonia at the time of their illness. It has been suggested that drugs that contain sulfa may exacerbate the severity of infection with E. chaffeensis [50] ; however, further studies are necessary to confirm this observation.
Several patients who died of infection with E. chaffeensis failed to mount IgG antibody responses by week 2 or 3 of illness; however, most patients in this series showed antibody responses that are similar both temporally and in magnitude to those observed in the general population [13, 36, 51] . All patients who survived their illness developed robust IgG antibody levels, including some patients with CD4+ T lymphocyte counts of <200 cells/,uL. As noted in earlier studies, diagnostic levels of IgG antibodies were not present in the first serum sample obtained from the majority of acutely ill patients in this series. Restricting serological evaluation to a single sample obtained during the acute phase of the illness may preclude laboratory confirmation of ehrlichioses [51] . For 4 patients, laboratory confirmation was obtained by using IFA as the only test. Patients infected with either E. chaffeensis or E. ewingii may demonstrate ?4-fold changes in titers of antibodies reactive with E. chaffeensis; this finding may prevent assignment of a specific agent if IFA is used as the sole confirmatory test [3, 15] . In this context, testing multiple samples by use of a combination of serological and molecular assays may be necessary to confirm the disease and to ascribe a species-specific etiology.
Successful outcomes after Ehrlichia-associated illnesses in HIV-infected patients can be achieved by using fundamental principles that apply to successful management of ehrlichioses in the general population. In this context, improving awareness among physicians and patients of the seasonal and geographic distribution of diseases caused by Ehrlichia species, eliciting pertinent epidemiological data in the patient history (e.g., a recent tick bite or exposure to ticks), and using an early presumptive diagnosis to guide empirical treatment with doxycycline remain the best approaches to combat these potentially fatal diseases.
